(STZ) Constellation Brands - Ratings and Ratios
Beer, Wine, Spirits
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 2.53% |
| Yield on Cost 5y | 2.47% |
| Yield CAGR 5y | 7.66% |
| Payout Consistency | 100.0% |
| Payout Ratio | 32.5% |
| Risk via 5d forecast | |
|---|---|
| Volatility | 31.6% |
| Value at Risk 5%th | 46.7% |
| Relative Tail Risk | -10.34% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.56 |
| Alpha | -40.50 |
| CAGR/Max DD | -0.21 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.632 |
| Beta | 0.486 |
| Beta Downside | 0.315 |
| Drawdowns 3y | |
|---|---|
| Max DD | 51.28% |
| Mean DD | 17.51% |
| Median DD | 10.52% |
Description: STZ Constellation Brands December 17, 2025
Constellation Brands Inc. (NYSE: STZ) is a diversified alcoholic-beverage company that produces, imports, markets, and sells a portfolio of beer, wine, and spirits across the United States, Canada, Mexico, New Zealand, and Italy. Its beer lineup includes the Corona family (e.g., Corona Extra, Corona Hard Seltzer) and Modelo brands, while its wine and spirits offerings feature names such as Robert Mondavi, Kim Crawford, High West, and Casa Noble. The firm distributes through wholesale partners, retail outlets, on-premise venues, and state alcohol-control agencies.
Key recent metrics: FY 2023 net sales were approximately $9.0 billion, up ~8 % YoY, driven largely by premium-segment growth and price-elastic demand for Corona Modelo in the U.S. market. Free cash flow generation averaged $1.2 billion, supporting a 2024 dividend increase of 8 % and a share-repurchase program. Sector drivers include rising consumer preference for premium and low-ABV products, while macro-economic headwinds-such as inflation-squeezed discretionary spending and potential excise-tax hikes-pose upside risk to margins.
For a deeper dive into STZ’s valuation and scenario analysis, consider checking out ValueRay’s research tools.
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income (1.11b TTM) > 0 and > 6% of Revenue (6% = 563.0m TTM) |
| FCFTA 0.08 (>2.0%) and ΔFCFTA 0.66pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 7.84% (prev 3.34%; Δ 4.50pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.12 (>3.0%) and CFO 2.70b > Net Income 1.11b (YES >=105%, WARN >=100%) |
| Net Debt (10.51b) to EBITDA (2.45b) ratio: 4.30 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.34 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (174.6m) change vs 12m ago -3.93% (target <= -2.0% for YES) |
| Gross Margin 51.96% (prev 50.18%; Δ 1.78pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 42.18% (prev 44.65%; Δ -2.47pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 5.45 (EBITDA TTM 2.45b / Interest Expense TTM 373.0m) >= 6 (WARN >= 3) |
Altman Z'' 3.91
| (A) 0.03 = (Total Current Assets 2.91b - Total Current Liabilities 2.17b) / Total Assets 21.68b |
| (B) 0.62 = Retained Earnings (Balance) 13.55b / Total Assets 21.68b |
| (C) 0.09 = EBIT TTM 2.03b / Avg Total Assets 22.24b |
| (D) 0.99 = Book Value of Equity 13.55b / Total Liabilities 13.68b |
| Total Rating: 3.91 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 65.32
| 1. Piotroski 5.50pt |
| 2. FCF Yield 4.88% |
| 3. FCF Margin 18.78% |
| 4. Debt/Equity 1.38 |
| 5. Debt/Ebitda 4.30 |
| 6. ROIC - WACC (= 3.49)% |
| 7. RoE 15.12% |
| 8. Rev. Trend 10.95% |
| 9. EPS Trend 42.66% |
What is the price of STZ shares?
Over the past week, the price has changed by +6.53%, over one month by +2.98%, over three months by +8.18% and over the past year by -16.26%.
Is STZ a buy, sell or hold?
- Strong Buy: 9
- Buy: 7
- Hold: 10
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the STZ price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 170.3 | 12.2% |
| Analysts Target Price | 170.3 | 12.2% |
| ValueRay Target Price | 151.6 | -0.2% |
STZ Fundamental Data Overview January 11, 2026
P/E Forward = 11.7096
P/S = 2.7275
P/B = 3.3401
P/EG = 1.5758
Beta = 0.444
Revenue TTM = 9.38b USD
EBIT TTM = 2.03b USD
EBITDA TTM = 2.45b USD
Long Term Debt = 10.29b USD (from longTermDebt, last quarter)
Short Term Debt = 378.7m USD (from shortTermDebt, last quarter)
Debt = 10.66b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 10.51b USD (from netDebt column, last quarter)
Enterprise Value = 36.10b USD (25.59b + Debt 10.66b - CCE 152.4m)
Interest Coverage Ratio = 5.45 (Ebit TTM 2.03b / Interest Expense TTM 373.0m)
EV/FCF = 20.49x (Enterprise Value 36.10b / FCF TTM 1.76b)
FCF Yield = 4.88% (FCF TTM 1.76b / Enterprise Value 36.10b)
FCF Margin = 18.78% (FCF TTM 1.76b / Revenue TTM 9.38b)
Net Margin = 11.83% (Net Income TTM 1.11b / Revenue TTM 9.38b)
Gross Margin = 51.96% ((Revenue TTM 9.38b - Cost of Revenue TTM 4.51b) / Revenue TTM)
Gross Margin QoQ = 53.23% (prev 52.80%)
Tobins Q-Ratio = 1.67 (Enterprise Value 36.10b / Total Assets 21.68b)
Interest Expense / Debt = 0.78% (Interest Expense 83.2m / Debt 10.66b)
Taxrate = 17.41% (110.1m / 632.3m)
NOPAT = 1.68b (EBIT 2.03b * (1 - 17.41%))
Current Ratio = 1.34 (Total Current Assets 2.91b / Total Current Liabilities 2.17b)
Debt / Equity = 1.38 (Debt 10.66b / totalStockholderEquity, last quarter 7.71b)
Debt / EBITDA = 4.30 (Net Debt 10.51b / EBITDA 2.45b)
Debt / FCF = 5.96 (Net Debt 10.51b / FCF TTM 1.76b)
Total Stockholder Equity = 7.34b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.99% (Net Income 1.11b / Total Assets 21.68b)
RoE = 15.12% (Net Income TTM 1.11b / Total Stockholder Equity 7.34b)
RoCE = 11.53% (EBIT 2.03b / Capital Employed (Equity 7.34b + L.T.Debt 10.29b))
RoIC = 9.12% (NOPAT 1.68b / Invested Capital 18.41b)
WACC = 5.63% (E(25.59b)/V(36.26b) * Re(7.71%) + D(10.66b)/V(36.26b) * Rd(0.78%) * (1-Tc(0.17)))
Discount Rate = 7.71% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -3.16%
[DCF Debug] Terminal Value 86.77% ; FCFF base≈1.74b ; Y1≈1.82b ; Y5≈2.11b
Fair Price DCF = 299.9 (EV 62.51b - Net Debt 10.51b = Equity 52.00b / Shares 173.4m; r=5.90% [WACC]; 5y FCF grow 4.94% → 2.90% )
EPS Correlation: 42.66 | EPS CAGR: 7.05% | SUE: 1.91 | # QB: 2
Revenue Correlation: 10.95 | Revenue CAGR: 1.49% | SUE: 1.48 | # QB: 1
EPS next Quarter (2026-05-31): EPS=3.35 | Chg30d=+0.023 | Revisions Net=-2 | Analysts=14
EPS next Year (2027-02-28): EPS=12.37 | Chg30d=-0.048 | Revisions Net=-6 | Growth EPS=+6.8% | Growth Revenue=+0.3%
Additional Sources for STZ Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle